Wells Fargo’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,391
| Closed | -$195 | – | 7675 |
|
|
2024
Q1 | $195 | Buy |
1,391
+80
| +6% | +$16 | ﹤0.01% | 6501 |
|
|
2023
Q4 | $190 | Sell |
1,311
-3,977
| -75% | -$618 | ﹤0.01% | 6622 |
|
|
2023
Q3 | $926 | Buy |
5,288
+3,038
| +135% | +$3.77K | ﹤0.01% | 6221 |
|
|
2023
Q2 | $7.02K | Buy |
2,250
+108
| +5% | +$321 | ﹤0.01% | 5998 |
|
|
2023
Q1 | $5.48K | Buy |
2,142
+2
| +0.1% | +$4 | ﹤0.01% | 6028 |
|
|
2022
Q4 | $3.19K | Buy |
2,140
+12
| +0.6% | +$19 | ﹤0.01% | 5896 |
|
|
2022
Q3 | $3K | Buy |
2,128
+65
| +3% | +$92 | ﹤0.01% | 6106 |
|
|
2022
Q2 | $3K | Buy |
2,063
+6
| +0.3% | +$10 | ﹤0.01% | 6250 |
|
|
2022
Q1 | $5K | Hold |
2,057
| – | – | ﹤0.01% | 6492 |
|
|
2021
Q4 | $9K | Sell |
2,057
-1,197
| -37% | -$3.96K | ﹤0.01% | 6597 |
|
|
2021
Q3 | $26K | Sell |
3,254
-3
| -0.1% | -$26 | ﹤0.01% | 5884 |
|
|
2021
Q2 | $32K | Sell |
3,257
-13,755
| -81% | -$112K | ﹤0.01% | 5735 |
|
|
2021
Q1 | $150K | Sell |
17,012
-17,599
| -51% | -$193K | ﹤0.01% | 5296 |
|
|
2020
Q4 | $354K | Buy |
34,611
+27,796
| +408% | +$304K | ﹤0.01% | 4774 |
|
|
2020
Q3 | $62K | Sell |
6,815
-9,403
| -58% | -$74.5K | ﹤0.01% | 5435 |
|
|
2020
Q2 | $116K | Buy |
16,218
+10,933
| +207% | +$116K | ﹤0.01% | 5157 |
|
|
2020
Q1 | $50K | Buy |
5,285
+5,148
| +3,758% | +$66.3K | ﹤0.01% | 5345 |
|
|
2019
Q4 | $2K | Buy |
+137
| New | +$1.67K | ﹤0.01% | 6198 |
|
Other funds holding GRTX
Wells Fargo's GRTX Position: Q2 2024 in Review
Wells Fargo sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2024, closing a stake of 1,391 shares — an estimated $195 sold.
Wells Fargo first reported a position in GRTX in Q4 2019 and held it in 18 quarters. The position peaked at $354K in Q4 2020. 1 fund tracked by Wall St. Rank holds GRTX as of Q2 2024.
- Wells Fargo reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 1,391 Galera Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $195.
- Wells Fargo first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 18 quarters.
- Wells Fargo's Galera Therapeutics, Inc. Common Stock position peaked at $354K in Q4 2020.
- 1 fund tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.